158 related articles for article (PubMed ID: 28787735)
1. Serum Growth Differentiation Factor 15 in Parkinson Disease.
Yao X; Wang D; Zhang L; Wang L; Zhao Z; Chen S; Wang X; Yue T; Liu Y
Neurodegener Dis; 2017; 17(6):251-260. PubMed ID: 28787735
[TBL] [Abstract][Full Text] [Related]
2. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
3. Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease.
Miyaue N; Yabe H; Nagai M
J Neurol Sci; 2020 Feb; 409():116616. PubMed ID: 31862518
[TBL] [Abstract][Full Text] [Related]
4. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
5. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
6. Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Shin MY; Kim JM; Kang YE; Kim MK; Joung KH; Lee JH; Kim KS; Kim HJ; Ku BJ; Shong M
J Korean Med Sci; 2016 Sep; 31(9):1413-8. PubMed ID: 27510384
[TBL] [Abstract][Full Text] [Related]
7. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis.
Li Z; Liu Y; Li X; Wu Y; Yang F; Mo Q; Chong Y
Biomed Res Int; 2020; 2020():5162541. PubMed ID: 33178828
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer.
Li C; Wang X; Casal I; Wang J; Li P; Zhang W; Xu E; Lai M; Zhang H
J Cell Mol Med; 2016 Aug; 20(8):1420-6. PubMed ID: 26990020
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum growth differentiation factor 15 in multiple system atrophy patients: A case control study.
Yue T; Lu H; Yao XM; Du X; Wang LL; Guo DD; Liu YM
World J Clin Cases; 2020 Jun; 8(12):2473-2483. PubMed ID: 32607324
[TBL] [Abstract][Full Text] [Related]
10. The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes.
He X; Su J; Ma X; Lu W; Zhu W; Wang Y; Bao Y; Zhou J
Cardiovasc Diabetol; 2020 Mar; 19(1):40. PubMed ID: 32222153
[TBL] [Abstract][Full Text] [Related]
11. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Andreadou E; Nikolaou C; Gournaras F; Rentzos M; Boufidou F; Tsoutsou A; Zournas C; Zissimopoulos V; Vassilopoulos D
Clin Neurol Neurosurg; 2009 Nov; 111(9):724-8. PubMed ID: 19632030
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
14. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
16. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis: A pilot study.
Song Y; Cui Y; Zhang X; Lin H; Zhang G; Zeng H; Zeng Y
Medicine (Baltimore); 2018 Dec; 97(51):e13733. PubMed ID: 30572513
[TBL] [Abstract][Full Text] [Related]
18. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease.
Godau J; Herfurth M; Kattner B; Gasser T; Berg D
J Neurol Neurosurg Psychiatry; 2010 May; 81(5):536-8. PubMed ID: 20176597
[TBL] [Abstract][Full Text] [Related]
19. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
20. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
